Compounds > levodopa
Page last updated: 2024-08-17

levodopa and ro 25-6981

levodopa has been researched along with ro 25-6981 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U1
Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C1
Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1

Other Studies

5 other study(ies) available for levodopa and ro 25-6981

ArticleYear
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Experimental neurology, 2004, Volume: 187, Issue:1

    Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate

2004
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    European journal of pharmacology, 2012, May-15, Volume: 683, Issue:1-3

    Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles

2012
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
    ACS chemical neuroscience, 2013, May-15, Volume: 4, Issue:5

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra

2013
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Neuropharmacology, 2013, Volume: 73

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes

2013
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007